MIDATECH PHARMA PLC SPON ADS EACH REP 5 ORD BDRX 深 滬
已收盤 06-18 16:00:00 美东时间
3.06
+0.050
+1.66%
華盛通- 最 高3.15
- 今 開3.1339
- 成交量 6520股
- 最 低 3.06
- 昨 收 3.01
- 總市值 228.31万
- 52周最高 66.50
- 市盈率 靜 --
- 換手率 0.87%
- 52周最低 2.86
- 委 比 77.35%
- 總股本 74.61万
- 歷史最高 797088271.056
- 量 比 0.25
- 振 幅 2.99%
- 歷史最低 3.0025
- 每 手 1
- 風險率 15.38%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Cellectar Biosciences (NASDAQ:CLRB) stock moved upwards by 45.0% to $4...
05-05 20:06
美股夜盘 | Mawson Infrastructure Group Inc涨40.15%，Organogenesis Holdings, Inc. Class A涨29.46%
Mawson Infrastructure Group Inc涨40.15%；Organogenesis Holdings, Inc. Class A涨29.46%；Alignment Healthcare, Inc.涨15.85%
04-07 15:01
美股夜盘 | Mawson Infrastructure Group Inc涨42.86%，Organogenesis Holdings, Inc. Class A涨20.54%
Mawson Infrastructure Group Inc涨42.86%；Organogenesis Holdings, Inc. Class A涨20.54%；Alignment Healthcare, Inc.涨15.85%
04-07 13:01
美股夜盘 | Mawson Infrastructure Group Inc涨36.29%，Organogenesis Holdings, Inc. Class A涨23.21%
Mawson Infrastructure Group Inc涨36.29%；Organogenesis Holdings, Inc. Class A涨23.21%；Alignment Healthcare, Inc.涨15.85%
04-07 09:01
Why Is Biodexa Pharmaceuticals (BDRX) Stock Skyrocketing Today?
Biodexa Pharmaceuticals shares are trading sharply higher Thursday afternoon after the company said it partnered with Syngene International.
04-03 01:15
Biodexa Pharma Partners With Syngene International To Manufacture Both MTX240 Active Pharmaceutical Ingredient And Dosage Form
Biodexa Announces Partnership with SyngeneTo Manufacture MTX240 GMP Clinical Trial SuppliesBiodexa Pharmaceuticals PLC (NASDAQ:BDRX) ("Biodexa" or "Company"), a clinical stage biopharmaceutical company developing a
04-02 20:37
Biodexa Pharmaceuticals To Implement 1-For-5 Reverse ADR Split, Changing ADR Ratio From 1:100,000 To 1:500,000 Ordinary Shares Effective April 6, 2026
Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of rare diseases with unmet medical needs, today announces a ratio
03-19 05:02
Biodexa Pharmaceuticals Adds New Phase 1 Ready Candidate To Its Portfolio To Treat Gastrointestinal Stromal Tumors
Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatment of rare diseases with an increasing focus on products to treat or
02-19 20:33
